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METHODS AND MATERIALS: One thousand four hundred forty-nine cases of early-stage
breast cancer underwent breast-conserving therapy with a single-lumen balloon-based applicator
used to deliver adjuvant accelerated partial breast irradiation (34 Gy in 10, bid fractions). One thou-
sand two hundred fifty-five cases (87%) had invasive breast cancer (median size5 10 mm) and 194
cases (13%) had ductal carcinoma in situ (DCIS; median size5 8 mm).
RESULTS: Patientswere stratified bymargin status into negative (n5 1326), close (!2mm; n5 110),
and positive (n5 13) margins. One hundred twenty-three cases (8.5%) had close or positive margins.
Overall, no statistical difference in the 6-year rate of ipsilateral breast tumor recurrence (IBTR) was
noted for close margins compared with that of margin-negative patients (8.7% vs. 4.1%, p5 0.10) or
for positive margins compared with that of margin-negative patients (14.3% vs. 4.1%, p5 0.41). In
patients with DCIS, there was a statistically significant increase in IBTR with close margins (17.6%
vs. 4.2%, p5 0.004) and when close and positive margins were pooled (15.7% vs. 4.2%, p5 0.01 with
a nonsignificant reduction in disease-free survival for DCIS patients with close margins (82.4% vs.
90.8%, p5 0.12). The increase in IBTR for close and close/positive patients was secondary to statisti-
cally significant increases in elsewhere failures rather than true recurrences/marginal misses.
CONCLUSION: Nonsignificant increases in the rates of IBTR were noted with close and positive
margins for invasive cancer with further data required to validate these findings.  2013 American
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Accelerated partial breast irradiation (APBI) represents
an adjuvant radiation therapy (RT) technique that allows
the delivery of a biologically equivalent dose to the lumpec-
tomy cavity compared with whole breast irradiation (WBI)
delivering 50 Gy while shortening the overall RT course to
1 week or less. At this time, APBI can be delivered using
multiple techniques including interstitial catheters, balloon
or strut-based single-entry devices, intraoperative applica-
tors, or external beam RT.With several series reporting more
than 5 years of follow-up, APBI has been shown to beOpen access under CC BY-NC-ND license.
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tionalWBI (1). Furthermore, when using the interstitial tech-
nique, 12-year data from a randomized trial along with
12-year retrospective data have been published, demon-
strating that APBI has equivalent outcomes to WBI (2, 3).
In women undergoing breast-conserving therapy (BCT),
rates of close/positive margins have been found to be up to
30% in somestudies (4, 5). Furthermore, some series have sug-
gested that close/positive margins may increase rates of local
recurrence; for example, data from Harvard University found
a significant difference between rates of local recurrence (27%
vs. 7%) inpatientswith positivemargins receivingWBI as part
of theirBCT,whereas another analysis evaluating focally posi-
tive margins did not (6, 7). At present, limited data exist on
outcomes in women with close/positive margins undergoing
APBI and the rates of ipsilateral breast tumor recurrence
(IBTR) as compared with women with negative margins
undergoing APBI. Currently, the American Society for Radi-
ation Oncology (ASTRO) Consensus Panel guidelines list
close margins (!2 mm) in the cautionary risk group and posi-
tive margins in the unsuitable risk group based predominantly
on a paucity of prospective data for these patients (8). There-
fore, the purpose of this analysis was to use the American
Society of Breast Surgeons (ASBrS) MammoSite (Hologic,
Inc., Bedford, MA) Registry Trial to examine the impact of
margin status on clinical outcomes in patients receivingAPBI.Methods and materials
The ASBrSMammoSite Registry Trial evaluated patients
receiving intracavitary brachytherapy as adjuvant RT via the
MammoSite single-lumen Radiation Therapy system (RTS)
catheter and consisted of 97 institutions treating a total of
1449 cases of early-stage breast cancer between May 4,
2002 and July 30, 2004. The goals and objectives of the
registry trial were to provide a forum to prospectively, objec-
tively, and systematically document data on the use and effi-
cacy of the applicator. Information on enrollment criteria,
data collection, treatment techniques, follow-up protocols,
and data management has previously been published
(9e11). In summary, patients received a total dose of
34 Gy, given as 3.4-Gy fractions, twice daily for 10 total frac-
tions to a point 1.0 cm from the surface of the balloon over
5e7 days using a remote high-dose-rate afterloader. After
the treatment, patients were followed-up either by their radi-
ation oncologist and/or surgeon and the data collected
included: cosmetic evaluation, use of adjuvant therapy,
imaging assessment, recurrence and treatment of recurrence,
survival status, and toxicities.
Over the course of the trial and in follow-up, two full-
service, independent contract research organizations, Syner-
gos, Inc. (The Woodlands, TX) and Biostat International
(BSI), Inc. (Tampa, FL) have provided data management
services as well as statistical analyses for the ASBrS Registry
Trial. Asmentioned in greater detail in previous publications,all paper records were verified to be entered into the database
accurately, site verification of recurrence information was
obtained and a reexamination of adverse event records for
terminology and missing descriptive information such as
grading and timing of onset was completed (9e11). Defini-
tions of recurrence and toxicity categories, and follow-up
visit windows, were provided by the ASBrS and its indepen-
dent scientific advisory committee to BSI. Management and
analysis of the data at BSI occurs only through in-depth
discussions between statisticians at BSI and the ASBrS.
For the purposes of this analysis, negative margins were
defined as greater than or equal to 2 mm between all inked
margins and the tumor. Close margins were defined as less
than 2 mm of space to an inked margin, and positive margins
were defined as ‘‘tumor on ink’’ (focal or otherwise). No
central pathology was performed and margin classifications
were based on reporting from the treating institution. An
IBTR was defined as the reappearance of breast cancer in
the treated breast before development of a distant metastasis
and was required to be confirmed pathologically (12). A true
recurrence/marginal miss (TR/MM) was defined as a recur-
rence of the treated cancer within or immediately adjacent
to the primary tumor site. An elsewhere failure (EF) was
defined as an IBTR several centimeters from the primary site.
Investigators were also asked to classify regional failures as
axillary, supraclavicular, or internal mammary in location.
Overall survival in this study reflected all deaths, cancer
related or otherwise, whereas cause-specific survival was
based on deaths attributed only to breast cancer. For this anal-
ysis, follow-up was complete by December 2011.Statistical methods
All time intervals were calculated from the date of Mam-
moSite RT system explantation. Differences in clinical,
pathologic, and treatment-related variables among negative-
margin and close-margin, positive-margin, and close/
positive-margin patients were performed via the pairwise
Wilcoxon rank sum test and pairwise c2 tests. Differences in
clinical outcomes were analyzed using the log-rank test.
KaplaneMeier tests were used to calculate clinical outcomes.
Univariate analysis of IBTR was performed for negative-
margin and close/positive-margin patients; within each group,
the analysis was repeated for invasive and ductal carcinoma
in situ (DCIS) cases separately. All tests were two sided and
declared statistically significant if the p-value was less than
or equal to 0.05. Version 8.0 or higher of the SAS (Cary,
NC) statistical software packagewas used to provide all statis-
tical analyses.Results
A total of 1440 patients with 1449 treated breasts were
analyzed including 1326 (91.5%) with negative margins,
110 (7.6%) with close margins, and 13 (0.9%) with positive
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negative patients, 64.5 months for women with close
margins, and 63.1 months for women with positive margins.
Patient demographics for all patients along with characteris-
tics for both invasive and DCIS patients are presented in
Tables 1e3 by margin status. Overall, patients with positive
margins (16.5 vs. 10.0 mm, p5 0.04) and the pooled close/
positive-margin (11.0 vs. 10.0 mm, p5 0.03) patients had
larger median tumor sizes than the negative-margin cohort.
Also, patients with close (13.6 vs. 9.2%, p5 0.01) or positive
(15.4% vs. 9.2%, p5 0.03) margins were more likely to be
estrogen receptor (ER) negative than the margin-negative
cohort. Positive-margin patients were more likely to be node
positive as well (15.4% vs. 2.5%, p5 0.01). With regards to
the invasive-only patients, those with positive margins were
more likely to be node positive (18.2% vs. 3.4%, p5 0.02)
thanmargin-negative patients. No differences in patient char-
acteristics by margin status were noted when evaluating
patients with pure DCIS, albeit with smaller numbers of
patients. Of note, no differences in the rates of systemic
therapy usage were noted for all patients.Table 1
Patient characteristics by margin status
Variables Negative Close
N 1326 110
Age, y
Median (range) 65.5 (31.8e93.5) 64.8 (40.9e8
Tumor size (mm)
Median (range) 10.0 (1.0e45.0) 11.0 (1.0e42
!5 116 (8.7) 13 (11.8)
$5e!10 450 (33.9) 29 (26.4)
$10e#20 646 (48.7) 54 (49.1)
O20 78 (5.9) 10 (9.1)
Unknown 36 (2.7) 4 (3.6)
AJCC tumor stage, N (%)
Tis 171 (12.9) 21 (19.1)
T1A 146 (11.0) 13 (11.8)
T1B 472 (35.6) 29 (26.4)
T1C 463 (34.9) 38 (34.5)
T2 73 (5.5) 9 (8.2)
Unknown 1 (0.1) 0
AJCC nodal stage, N (%)
N0 1111 (83.8) 86 (78.2)
NX 182 (13.7) 21 (19.1)
N (þ) 33 (2.5) 3 (2.7)
Estrogen receptor, N (%)
Positive 869 (65.5) 57 (51.8)
Negative 122 (9.2) 15 (13.6)
Unknown 335 (25.3) 38 (34.5)
Systemic therapy, N (%)
Chemotherapy alone 75 (5.7) 6 (5.5)
Hormonal therapy alone 733 (55.3) 63 (57.3)
Both chemotherapy and hormonal therapy 77 (5.8) 5 (4.5)
None/unknown 441 (33.3) 36 (32.7)
Follow-up (mo)
Median 58.5 64.5
Mean 54.7 59.1
Range 0.0e107.8 0.4e95.4
AJCC5American Joint Committee on Cancer; N (%)5 number of patients
a Statistically significant, all p-values are in comparison with negative-margClinical outcomes by margin status and disease
histology are presented in Table 4. Overall, no statistically
significant difference in the 6-year rate of IBTR was noted
for patients with close margins compared with that of
negative-margin patients (8.7% vs. 4.1%, p5 0.10) despite
a nearly twofold increase. Positive-margin patients had
a nonsignificant increase in IBTR (14.3% vs. 4.1%,
p5 0.41); however, when both groups were pooled, a trend
toward higher rates of IBTR in patients with involved
margins was noted (9.3% vs. 4.1%, p5 0.07). Statistically
significant increases in EFs were noted for close (6.8% vs.
2.6%, p5 0.04) and close/positive-margin (7.7% vs. 2.6%,
p5 0.02) patients compared with negative-margin patients;
however, no differences in TR/MM were noted. No differ-
ences emerged in the rates of regional nodal failure, distant
metastases, disease-free survival (DFS), cause-specific
survival, or overall survival by margin status in the entire
cohort.
When examining invasive-only patients, no significant
differences in the rates of IBTR were noted for patients
with positive margins (20.0% vs. 4.1%, p5 0.30), thosep-Value Positive p-Value Close/positive p-Value
13 123
8.5) 0.75 72.0 (46.9e89.2) 0.19 65.2 (40.9e89.2) 0.92
.0) 0.11 16.5 (1.0e45.0) 0.04a 11.0 (1.0e45.0) 0.03a
1 (7.7) 14 (11.4)
3 (23.1) 32 (26.0)
5 (38.5) 59 (48.0)
3 (23.1) 13 (10.6)
1 (7.7) 5 (4.1)
0.23 2 (15.4) 0.76 23 (18.7) 0.17
1 (7.7) 14 (11.4)
4 (30.8) 33 (26.8)
4 (30.8) 42 (34.1)
2 (15.4) 11 (8.9)
0 0
0.29 8 (61.5) 0.01a 94 (76.4) 0.11
3 (23.1) 24 (19.5)
2 (15.4) 5 (4.1)
0.01a 4 (30.8) 0.03a 61 (49.6) 0.002a
2 (15.4) 17 (13.8)
7 (53.8) 45 (36.6)
0.84 1 (7.7) 0.33 7 (5.7) 0.99
6 (46.2) 69 (56.1)
2 (15.4) 7 (5.7)
4 (30.8) 40 (32.5)
0.08 63.1 0.56 63.1 0.06
58 59
0.4e90.0 0.4e95.4
(percentage of patients).
in group.
Table 2
Characteristics of patients with invasive breast cancer
Variables Negative margins Close margins p-Value Positive margins p-Value Close/positive margins p-Value
Number treated 1155 89 11 100
Age, y
Median (range) 65.9 (31.8e93.5) 67.4 (40.9e88.5) 0.88 75.0 (46.9e89.2) 0.16 67.5 (40.9e89.2) 0.56
Tumor size (mm)
Median (range) 10.0 (1.0e35.0) 11.0 (2.0e42.0) 0.11 15.0 (1.0e30.0) 0.11 11.0 (1.0e42.0) 0.05a
!5 80 (6.9) 8 (9.0) 1 (9.1) 9 (9.0)
$5e!10 402 (34.8) 26 (29.2) 3 (27.3) 29 (29.0)
$10e#20 600 (51.9) 47 (52.8) 5 (45.5) 52 (52.0)
O20 69 (6.0) 8 (9.0) 2 (18.2) 10 (10.0)
Unknown 5 (0.3) 0 0 0
AJCC tumor stage, N (%)
T1a 146 (12.6) 13 (14.6) 0.45 1 (9.1) 0.63 14 (14.0) 0.32
T1b 472 (40.9) 29 (32.6) 4 (36.4) 33 (33.0)
T1c 463 (40.1) 38 (42.7) 4 (36.4) 42 (42.0)
T2 73 (6.3) 9 (10.1) 2 (18.2) 11 (11.0)
Unknown 1 (0.1) 0 0 0
AJCC nodal stage, N (%)
N0 1062 (91.9) 82 (92.1) 0.93 8 (72.7) 0.02a 90 (90.0) 0.49
NX 60 (5.2) 4 (4.5) 1 (9.1) 5 (5.0)
N (þ) 33 (2.9) 3 (3.4) 2 (18.2) 5 (5.0)
Estrogen receptor, N (%)
Positive 818 (70.8) 51 (57.3) 0.02a 4 (36.4) 0.04a 55 (55.0) 0.004a
Negative 111 (9.6) 14 (15.7) 2 (18.2) 16 (16.0)
Unknown 226 (19.6) 24 (27.0) 5 (45.5) 29 (29.0)
Systemic therapy, N (%)
Chemotherapy alone 75 (6.5) 6 (6.7) 0.90 1 (9.1) 0.20 7 (7.0) 0.98
Hormonal therapy alone 644 (55.8) 52 (58.4) 4 (36.4) 56 (56.0)
Both chemo and hormonal therapy 77 (6.7) 5 (5.6) 2 (18.2) 7 (7.0)
None/unknown 359 (31.1) 26 (29.2) 4 (36.4) 30 (30.0)
Follow-up (mo)
Median 58.4 67.2 0.03a 59.9 0.85 66.5 0.04a
Mean 54.5 60.1 54.6 59.5
Range 0.0e107.8 0.4e95.4 0.4e90.0 0.4e95.4
AJCC5American Joint Committee on Cancer; N (%)5 number of patients (percentage of patients).
a Statistically significant, all p-values are in comparison with negative-margin group.
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with pooled close/positive margins (7.5% vs. 4.1%,
p5 0.43). Furthermore, no differences emerged in the
rates of regional nodal failure, distant metastases, DFS,
cause-specific survival, or overall survival by margin
status for invasive-only patients.
When evaluating patients with DCIS only, there was
a statistically significant increase in IBTR when patients
had close margins (17.6% vs. 4.2%, p5 0.004) and when
close and positive margins were pooled (15.7% vs. 4.2%,
p5 0.01). This significant increase in IBTR led to a nonsig-
nificant reduction in DFS in patients with noninvasive
disease who had close surgical margins (82.4% vs.
90.8%, p5 0.17). Statistically significant increases in EFs
were noted for close-margin (17.6% vs. 1.5%, p!0.001)
and close/positive-margin (15.7% vs. 1.5%, p!0.001)
patients compared with negative-margin patients; however,
no differences in TR/MM were noted.
Univariate analysis of IBTR was performed for patients
with negative and close/positive margins and is presented in
Table 5. For close/positive margins, age was associatedwith a trend for IBTR ( p5 0.07), whereas in the DCIS
subset a trend was noted for age ( p5 0.07), grade
( p5 0.07), and hormonal therapy ( p5 0.07). For
negative-margin patients, ER negativity ( p!0.001) and
extensive intraductal component ( p5 0.05) were signifi-
cantly associated with IBTR.Discussion
The results of this analysis confirm previous publica-
tions highlighting the efficacy of APBI using intracavitary
brachytherapy in women who are appropriately selected.
The first conclusion drawn from our analysis is that
although no significant differences in IBTR were found
between patients treated with APBI with negative vs. close
or positive margins, a trend ( p5 0.07) was noted when
close and positive margins were pooled. Of note, the rates
of IBTR were greater than twofold higher for close margins
and greater than threefold higher for positive margins.
Although not reaching statistically significant values, these
Table 3
Characteristics of patients with ductal carcinoma in situ
Variables Negative Close p-Value Positive p-Value Close/positive p-Value
Number treated 171 21 2 23
Age, y
Median (range) 62.1 (40.7e88.0) 60.6 (44.0e78.8) 0.44 64.7 (57.4e72.0) 0.97 60.6 (44.0e78.8) 0.47
Tumor size (mm)
Median (range) 8.0 (1.0e45.0) 10.0 (1.0e30.0) 0.42 45.0 (45.0) 0.09 10.5 (1.0e45.0) 0.25
!5 36 (21.1) 5 (23.8) 0 (0.0) 5 (21.7)
O5e!10 48 (28.1) 3 (14.3) 0 (0.0) 3 (13.0)
O10e!20 46 (26.9) 7 (33.3) 0 (0.0) 7 (30.4)
O20 9 (5.3) 2 (9.5) 1 (50.0) 3 (13.0)
Unknown 32 (18.7) 4 (19.0) 1 (50.0) 5 (21.7)
AJCC nodal stage, N (%)
N0 49 (28.7) 4 (19.0) 0.35 0 (0.0) 0.37 4 (17.4) 0.26
NX 122 (71.3) 17 (81.0) 2 (100.0) 19 (82.6)
Estrogen receptor, N (%)
Positive 51 (29.8) 6 (28.6) 0.94 0 (0.0) 0.57 6 (26.1) 0.84
Negative 11 (6.4) 1 (4.8) 0 (0.0) 1 (4.3)
Unknown 109 (63.7) 14 (66.7) 2 (100.0) 16 (69.6)
Systemic therapy, N (%)
Hormonal therapy 89 (52.0) 11 (52.4) d 2 (100.0) 13 (56.5) d
None/unknown 82 (48.0) 10 (47.6) 0 10 (43.5)
Follow-up (mo)
Median 59.4 55.1 0.79 76.3 0.37 58.2 0.99
Mean 55.9 54.9 76.3 56.8
Range 0.0e104.6 13.0e91.1 71.4e81.2 13.0e91.1
AJCC5American Joint Committee on Cancer; N (%)5 number of patients (percentage of patients).
All p-values are in comparison with negative-margin group.
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reasonable attempts to achieve negative margins should
be made before the delivery of RT. An earlier analysis of
the ASBrS Registry had found that margin status was not
associated with IBTR in invasive cancers ( p5 0.75),
whereas a statistically significant association was noted in
patients with DCIS (hazard ratio5 7.81, p5 0.01) (13).
Our updated analysis, however, found nonsignificant
increases in IBTR for invasive and significant increases
for DCIS patients. This analysis is supported by data from
William Beaumont Hospital evaluating the impact of
margin status on IBTR that also found a nonsignificant
decrease in local control for close/positive margins
( p5 0.07) (14). It should be noted that positive-margin
cases did represent higher risk cases with patients having
larger tumors and were more likely to be ER-negative
tumors. Previous studies have confirmed ER negativity
as a risk factor for IBTR, which was confirmed in our
univariate analysis as well (15). At this time, the current
analysis continue to support the use of margin status in
identifying suitable patients for partial breast irradiation,
which is in agreement with the American Society for Radi-
ation Oncology and Groupe Europeen de Curietherapie-
European Society of Therapeutic Radiology and Oncology
guidelines (8, 16).
A second conclusion that can be inferred from this anal-
ysis and review of the literature is that outcomes in patients
with close or positive margins may be similar between
partial breast irradiation and WBI cases. As previouslymentioned, an analysis by Park et al. (6) found an 8-year
IBTR rate of 27% for extensively positive margins and
14% for focally positive margins in patients treated with
WBI (vs. 7% for negative margins), which is comparable
with our data. Furthermore, an analysis by the University
of Wurzburg found a 9.3% rate of local recurrence in
patients with uncertain or positive margins treated with
BCT (17). These findings suggest that if women with close
or positive margins wish to proceed with BCT without re-
excision, similar increased rates of IBTR would be ex-
pected regardless of whether they are treated with WBI
or APBI. It is important, however, to emphasize that no
direct comparison has been made between WBI and APBI
in our series and that we should wait for data from prospec-
tive randomized Phase III trials comparing WBI and APBI
to make more informed decisions regarding the risks asso-
ciated with close or positive margins in the setting of partial
breast irradiation.
With 6-year follow-up, the rate of IBTR was 8.7% for
close, 14.3% for positive, and 9.3% when pooled close
and positive margins were combined. With these numbers
at 6 years, as follow-up is extended beyond 10 years, local
recurrences may exceed 20%. This suggests that in patients
with close/positive margins, reexcision should be attempted
initially if feasible. This represents one of the benefits of
intracavitary brachytherapy over intraoperative radiation;
target margins can be assessed before the treatment and
the therapeutic plan adjusted based on these margin find-
ings. Should patients be found to have a close/positive
Table 4
Six-year clinical outcomes by margin status
All patients
Negative, %
(N5 1326)
Close, %
(N5 110) p-Value
Positive, %
(N5 13) p-Value
Close/positive, %
(N5 123) p-Value
Ipsilateral breast tumor recurrence 4.08 8.65 0.10 14.30 0.41 9.34 0.07
TR/MM failure 1.53 2.00 0.90 0 0.71 1.79 0.81
Elsewhere failure 2.59 6.79 0.04a 14.30 0.21 7.69 0.02a
Regional failure 0.76 0.95 0.75 0 0.78 0.85 0.83
Distant metastases 2.66 4.04 0.68 0 0.60 3.59 0.82
Disease-free survival 84.10 79.40 0.18 77.90 0.43 79.20 0.14
Overall survival 90.30 91.50 0.92 90.90 0.42 91.50 0.74
Cause-specific survival 98.20 99.00 0.57 100 0.65 99.10 0.50
Contralateral failure 2.57 1.06 0.41 0 0.60 0.95 0.34
Invasive patients
Negative, %
(N 5 1155)
Close, %
(N 5 89) p-Value
Positive, %
(N 5 11) p-Value
Close/positive, %
(N 5 100) p-Value
Ipsilateral breast tumor recurrence 4.05 6.22 0.62 20.00 0.30 7.54 0.43
TR/MM failure 1.34 2.27 0.86 0 0.75 2.08 0.95
Elsewhere failure 2.74 4.03 0.63 20.00 0.16 5.58 0.38
Regional failure 0.87 1.19 0.71 0 0.78 1.06 0.79
Distant metastases 2.95 4.85 0.57 0 0.63 4.33 0.70
Disease-free survival 83.10 78.80 0.28 71.10 0.30 78.30 0.19
Overall survival 89.50 89.70 0.69 88.90 0.31 89.70 0.50
Cause-specific survival 98.10 98.70 0.64 100 0.67 98.90 0.57
Contralateral failure 2.74 1.30 0.49 0 0.63 1.16 0.42
Ductal carcinoma in situ patients
Negative, %
(N5 171)
Close, %
(N5 21) p-Value
Positive, %
(N5 2) p-Value
Close/positive, %
(N5 23) p-Value
Ipsilateral breast tumor recurrence 4.19 17.60 0.004a 0 0.77 15.70 0.01a
TR/MM failure 2.75 0 0.56 0 0.81 0 0.53
Elsewhere failure 1.48 17.6 !0.001a 0 0.86 15.7 !0.001a
Distant metastases 0.74 0 0.73 0 0.90 0 0.71
Disease-free survival 90.80 82.40 0.17 100 0.65 84.30 0.26
Overall survival 95.60 100 0.41 100 0.74 100 0.37
Cause-specific survival 99.20 100 0.72 100 0.90 100 0.71
Contralateral failure 1.45 0 0.61 0 0.87 0 0.59
TR/MM5 true recurrence/marginal miss.
a
Statistically significant, all p-values are in comparison with negative-margin group.
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can be switched to a WBI course with boost therapy.
Finally, when examining the IBTR in patients with
close/positive margins, close to 80% of the failures were
EFs, likely secondary to the high rate of EFs in DCIS
patients with close/positive margins. These data are not
consistent with the previous reports from Yale University
and the British Columbia Cancer Agency, which found
the rate of EFs to be approximately 50% in patients under-
going BCTwith WBI (18, 19). The etiology of this discrep-
ancy may be that in patients with DCIS, positive/close
margins may portend a risk of subclinical disease with
potential multifocality/multicentricity. Also, the subjective
nature of the TR/MM vs. elsewhere classification may play
a role in the discrepancy.
There are limitations to our analysis. Although data
were collected prospectively through the ASBrS Registry,
this represents an unplanned retrospective analysis.
Furthermore, owing to the small numbers of close/positive
margin and limited number of failures, the power to detect
differences was limited. This is likely the reason that the
large differences seen in IBTR in this analysis werenonsignificant. Also, margin status is predicated on the
extent of positive margins; however, the ASBrS Registry
does not collect the extent of close or positive margins
(number of positive margins, invasive vs. both invasive/
noninvasive involvement, linear extent, attempts at reexci-
sion, etc), which limits definitive conclusions on this
information. In addition, margin status was based on
a review of reports from multiple institutions with varying
ways of assessing margins pathologically, and the ASBrS
Registry Trial did not perform a central retrospective path-
ologic review or require a central tissue banking. It is
interesting to note that the length of follow-up trended
toward significance with close/positive-margin patients
having longer follow-up than negative-margin patients
(63.1 vs. 58.5 months, p5 0.06). This may represent
surgeons increasingly attempting to achieve wider surgical
margins in patients selected for APBI or a change in
patient selection. Despite these limitations, this analysis
represents the largest collection of close/positive-margin
APBI patients evaluated to date and supports the recom-
mendation to obtain margins of 2 mm or greater before
the adjuvant application of APBI.
Table 5
Univariate analysis of ipsilateral breast tumor recurrence
Variables
Negative margin Close/positive margin
All cases
(N5 1326)
Invasive cases
(N5 1155)
DCIS cases
(N5 171)
All cases
(N5 123)
Invasive cases
(N5 100)
DCIS cases
(N5 23)
p-Value
Age (continuous) 0.51 0.51 0.92 0.07 (Younger) 0.18 0.31
Age at diagnosis (!50 vs.$50 y) 1.00 0.76 0.41 0.07 (!50) 0.48 0.07 (!50)
Tumor size (continuous variable) 0.91 0.94 0.96 0.09 (Increasing) 0.30 0.27
Nodal status (negative vs.
positive)
1.00 1.00 d 1.00 1.00 d
Overall stage (T2 vs. T1dIBC
only)
1.00 1.00 d 1.00 1.00
Estrogen receptor status (positive
vs. negative)
!0.001a (Negative) !0.001a (Negative) 0.33 0.64 0.31 1.00
Histologic grade (Grade I/II vs.
Grade III/IV)
0.06 (High grade) 0.14 0.16 0.14 0.65 0.07 (Low grade)
Chemotherapy use (yes vs. no) 1.00 0.81 d 1.00 0.54 d
Adjuvant hormone therapy (yes
vs. no)
0.53 0.39 0.68 0.26 1.00 0.07 (No)
EIC (positive vs. negativedIBC
only)
0.05a (Positive) 0.05a (Positive) d 1.00 1.00
Method of placement (closed
cavity vs. open cavity)
0.27 0.74 0.02a (Closed) 1.00 0.39 0.59
ASTRO Grouping (I/II vs. III) 0.40 0.49 1.00 0.12 0.61 1.00
Applicator-to-skin distance
(continuous variable)
0.22 0.14 0.44 0.81 0.31 0.35
DCIS5Ductal carcinoma in situ; IBC5 invasive breast cancer; EIC5 extensive intraductal component; ASTRO5American Society of Radiation
Oncology; IBTR5 ipsilateral breast tumor recurrence.
a Statistically significant, for cases with p!0.10, factor with higher rate of IBTR listed in parentheses.
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Good clinical outcomes were seen in patients under-
going APBI regardless of margin status. However, nonsig-
nificant increases in the rates of IBTR were noted in
patients with close or positive margins similar to what is
observed with WBI. Statistically significant increases in
IBTR were noted for DCIS patients with close margins.
Further prospective studies are required to validate these
results and define the appropriate margin status for patients
undergoing APBI.References
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